omeprazole has been researched along with naproxen in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (8.57) | 18.2507 |
| 2000's | 18 (51.43) | 29.6817 |
| 2010's | 11 (31.43) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Gudjónsson, H; Oddsson, E; Thjódleifsson, B | 1 |
| Lanas Arbeloa, A; Serrano Aulló, MT | 1 |
| Andersson, T; Bredberg, E; Lagerström, PO; Naesdal, J; Wilson, I | 1 |
| Chan, FK; Chan, HL; Chung, SC; Hui, Y; Lai, MS; Lau, JY; Lee, YT; Leung, VK; Leung, WK; Suen, BY; Sung, JJ; Wu, JC | 1 |
| Miyake, K; Sakamoto, C | 1 |
| Curran, MP; Wellington, K | 1 |
| Eisen, GM; Fort, JG; Goldstein, JL; Gralnek, IM; Lewis, B; Zlotnick, S | 1 |
| Brotze, S; Connor, M; Jaworski, T; Roeser, K; Sarosiek, I; Sarosiek, J; Sostarich, S; Wallner, G | 1 |
| Chiou, CF; Ofman, JJ; Spiegel, BM | 1 |
| Amer, F; Andhivarothai, N; Kukulka, MJ; Vakily, M | 1 |
| Scheiman, JM | 1 |
| Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM | 1 |
| Aisenberg, J; Benson, AA; Bodian, CA; Cohen, LB; Desai, JC; Goo, T; Miller, KM; Sanyal, SM | 1 |
| Albert, J; Arulmani, U; Bolten, W; Ell, C; Fortun, P; Hawkey, CJ; Hugot, JL; Keuchel, M; Krammer, G; McAlindon, M; Rebuli, R; Schumann, S; Shonde, A; Simon, B; Toth, E; Yu, V | 1 |
| Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W | 1 |
| Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL | 1 |
| Blackler, R; Bolla, M; Ongini, E; Syer, S; Wallace, JL | 1 |
| Camacho-Muñoz, D; Kasprzyk-Hordern, B; Thomas, KV | 1 |
| El-Kimary, EI; Ragab, MAA | 1 |
| Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA | 1 |
| Kassie, GM; Kerr, M; Moffat, A; Pratt, N; Roughead, EE | 1 |
5 review(s) available for omeprazole and naproxen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Gastric lesion caused by NSAID and inflammation due to Helicobacter pylori. Is there potentiation or attenuation?].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Confidence Intervals; Duodenal Ulcer; Enzyme Inhibitors; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic; Naproxen; Omeprazole; Peptic Ulcer; Prospective Studies; Ranitidine; Risk Factors; Stomach Ulcer | 1998 |
[Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Delivery Systems; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Isoenzymes; Lactones; Membrane Proteins; Naproxen; Omeprazole; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Sulfones | 2002 |
Delayed-release lansoprazole plus naproxen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Lansoprazole; Naproxen; Omeprazole; Ulcer | 2004 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Lactones; Lansoprazole; Naproxen; Omeprazole; Proton Pump Inhibitors; Pyrazoles; Rheumatology; Sulfonamides; Sulfones | 2005 |
9 trial(s) available for omeprazole and naproxen
| Article | Year |
|---|---|
Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen.
Topics: Acute Disease; Adult; Double-Blind Method; Duodenum; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Humans; Intestinal Mucosa; Male; Naproxen; Omeprazole; Ranitidine | 1992 |
Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cross-Over Studies; Diclofenac; Drug Interactions; Female; Humans; Male; Naproxen; Omeprazole; Piroxicam | 1998 |
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Naproxen; Omeprazole; Organometallic Compounds; Secondary Prevention; Tetracycline | 2001 |
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.
Topics: Adolescent; Adult; Aged; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Humans; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Naproxen; Omeprazole; Probability; Prospective Studies; Pyrazoles; Reference Values; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Sulfonamides; Video Recording | 2005 |
Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Dizziness; Dose-Response Relationship, Drug; Female; Headache; Humans; Lansoprazole; Male; Metabolic Clearance Rate; Methotrexate; Middle Aged; Naproxen; Nausea; Omeprazole; Vomiting | 2005 |
What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?
Topics: Adult; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Naproxen; Omeprazole; Prospective Studies; Pyrazoles; Sulfonamides | 2005 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Middle Aged; Naproxen; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prospective Studies; Proton Pump Inhibitors; Pyrazoles; Recurrence; Risk Factors; Sulfonamides; Treatment Outcome | 2005 |
Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Duodenal Ulcer; Duodenoscopy; Dyspepsia; Female; Gastroscopy; Helicobacter pylori; Humans; Male; Middle Aged; Naproxen; Omeprazole; Pilot Projects; Proton Pump Inhibitors; Reference Values; Stomach Ulcer; Treatment Outcome | 2008 |
Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
Topics: Administration, Oral; Adult; Aged; Capsule Endoscopes; Cross-Over Studies; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Humans; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Naproxen; Omeprazole; Probability; Reference Values; Risk Assessment; Ulcer | 2008 |
21 other study(ies) available for omeprazole and naproxen
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Long-term prophylaxis with omeprazol is superior to eradication therapy in H. pylori-positive NSAIDs taking patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Helicobacter Infections; Helicobacter pylori; Humans; Long-Term Care; Naproxen; Omeprazole; Peptic Ulcer Hemorrhage; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2002 |
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endoscopy, Digestive System; Gastric Mucosa; Humans; Intestinal Mucosa; Isoenzymes; Membrane Proteins; Middle Aged; Naproxen; Omeprazole; Osteoarthritis; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides | 2004 |
Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Exocrine Glands; Female; Gastric Juice; Gastric Mucins; Humans; Male; Middle Aged; Mucus; Naproxen; Omeprazole; Proton-Translocating ATPases; Rabeprazole | 2005 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Atorvastatin; Calcium Carbonate; Cardiomyopathy, Restrictive; Citalopram; Connective Tissue Diseases; Diuretics; Female; Furosemide; Glucosamine; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Lupus Erythematosus, Systemic; Magnesium; Metolazone; Middle Aged; Naproxen; Omeprazole; Potassium Chloride; Prednisone; Pyrroles; Selective Serotonin Reuptake Inhibitors; Spironolactone | 2008 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacterium; Celecoxib; Colon; Denaturing Gradient Gel Electrophoresis; Disease Models, Animal; Drug Interactions; Gastrointestinal Hemorrhage; Hematocrit; Jejunum; Lansoprazole; Male; Naproxen; Omeprazole; Peptic Ulcer; Probiotics; Proton Pump Inhibitors; Pyrazoles; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Time Factors | 2011 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combination; Gastric Mucosa; Gastrointestinal Diseases; Gastrointestinal Tract; Hypertension; Male; Naproxen; Nitrates; Obesity; Omeprazole; Pyrazoles; Rats; Rats, Inbred SHR; Rats, Wistar; Rats, Zucker; Sulfonamides | 2012 |
Enantioselective simultaneous analysis of selected pharmaceuticals in environmental samples by ultrahigh performance supercritical fluid based chromatography tandem mass spectrometry.
Topics: Aminorex; Carbazoles; Chloramphenicol; Chromatography, High Pressure Liquid; Chromatography, Supercritical Fluid; Flurbiprofen; Humans; Ibuprofen; Ifosfamide; Imidazoles; Indoprofen; Molecular Structure; Naproxen; Ofloxacin; Omeprazole; Praziquantel; Solid Phase Extraction; Stereoisomerism; Tandem Mass Spectrometry; Tetramisole; Water Pollutants, Chemical | 2016 |
High performance liquid chromatography with photo diode array for separation and analysis of naproxen and esomeprazole in presence of their chiral impurities: Enantiomeric purity determination in tablets.
Topics: 2-Propanol; Chromatography, High Pressure Liquid; Esomeprazole; Hexanes; Limit of Detection; Naproxen; Omeprazole; Reproducibility of Results; Stereoisomerism; Tablets; Trifluoroacetic Acid | 2017 |
RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Naproxen; Omeprazole; Research Design; Tinidazole | 2022 |
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Amlodipine; Amphotericin B; Australia; Case-Control Studies; Ciprofloxacin; Diclofenac; Furosemide; Humans; Ibuprofen; Metformin; Naproxen; Omeprazole; Primary Health Care; Ramipril; Simvastatin; Spironolactone; Sulfamethoxazole; Telmisartan; Trimethoprim; Valacyclovir; Zoledronic Acid | 2022 |